Literature DB >> 8829276

Radioiodine and thyroid disease: the beginning.

D V Becker1, C T Sawin.   

Abstract

In 1936, Karl Compton, then president of the Massachusetts Institute of Technology (MIT) and the thyroid group of the Massachusetts General Hospital (MGH), undertook a joint study that led to the production of small amounts of short-lived radioiodine (iodine 128, half-life, 25 min). The original intent was to use it for diagnosis and treatment of thyroid disease, but in order to explore the underlying physiology, their first work was performed in rabbits and published in 1938. It clearly showed that the radioiodine was selectively and avidly taken up by the thyroid gland. It was immediately apparent to the MGH-MIT group and another team working at the Berkeley, CA cyclotron that longer-lasting iodine isotopes were needed, and soon both developed procedures for cyclotron-produced 130 (half-life, 12.5 hr) and 131I (half-life, 8 d). In 1939, the Berkeley group, using 131I, was the first to show that the normal human thyroid gland accumulated radioiodine. By 1941, the MGH-MIT team, using mainly 130I, was able to successfully treat a few patients with hyperthyroidism, and so achieved their original goal. The Berkeley group did the same a few months later, using mainly 131I. Both presented results at the same meeting of the American Society for Clinical Investigation in Atlantic City, NJ in the spring of 1942. This was in the midst of World War II and it was not easy to get much 130I or 131I, so experience was limited. Although effective, radioiodine treatment of hyperthyroidism had not been widely adopted by the end of the war in 1945, partly because radioiodine remained in short supply and partly because another medical therapy for hyperthyroidism, antithyroid drugs, had been invented. However, by 1946, fission-derived radioiodine became readily available as a by-product of the Manhattan project in Oak Ridge, TN; hundreds of patients were treated within a few years, both for hyperthyroidism and for thyroid cancer. A new treatment, based on the physiological application of a radioisotope of iodine, was then a reality.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8829276     DOI: 10.1016/s0001-2998(96)80020-1

Source DB:  PubMed          Journal:  Semin Nucl Med        ISSN: 0001-2998            Impact factor:   4.446


  11 in total

Review 1.  [Radionuclide therapy of endocrine-related cancer].

Authors:  C Kratochwil; F L Giesel
Journal:  Radiologe       Date:  2014-10       Impact factor: 0.635

2.  Measuring the actual I-131 thyroid uptake curve with a collar detector system: a feasibility study.

Authors:  Peter Brinks; Koen Van Gils; Ellen Kranenborg; Jules Lavalaye; Dennis B M Dickerscheid; Jan B A Habraken
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-12-17       Impact factor: 9.236

Review 3.  2022 Update on Clinical Management of Graves Disease and Thyroid Eye Disease.

Authors:  Thanh D Hoang; Derek J Stocker; Eva L Chou; Henry B Burch
Journal:  Endocrinol Metab Clin North Am       Date:  2022-05-11       Impact factor: 4.748

4.  Second primary malignancy risk in thyroid cancer and matched patients with and without radioiodine therapy analysis from the observational health data sciences and informatics.

Authors:  Seok Kim; Ji-In Bang; Dachung Boo; Borham Kim; In Young Choi; SooJeong Ko; Ie Ryung Yoo; Kwangsoo Kim; Junmo Kim; YoungHwan Joo; Hyun Gee Ryoo; Jin Chul Paeng; Jung Mi Park; Woncheol Jang; Byungwon Kim; Yangha Chung; Dongyoon Yang; Sooyoung Yoo; Ho-Young Lee
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-04-01       Impact factor: 10.057

5.  Early Sialadenitis After Radioactive Iodine Therapy for Differentiated Thyroid Cancer: Prevalence and Predictors.

Authors:  Ruba Riachy; Nisrine Ghazal; Mohamad B Haidar; Ahmad Elamine; Mona P Nasrallah
Journal:  Int J Endocrinol       Date:  2020-08-04       Impact factor: 3.257

6.  Improved Patient Dosimetry at Radioiodine Therapy by Combining the ICRP Compartment Model and the EANM Pre-Therapeutic Standard Procedure for Benign Thyroid Diseases.

Authors:  Martin Andersson; Sören Mattsson
Journal:  Front Endocrinol (Lausanne)       Date:  2021-03-12       Impact factor: 5.555

Review 7.  Modulation of Secondary Cancer Risks from Radiation Exposure by Sex, Age and Gonadal Hormone Status: Progress, Opportunities and Challenges.

Authors:  Anat Biegon; Siobhan Cohen; Dinko Franceschi
Journal:  J Pers Med       Date:  2022-04-30

8.  Treatment of differentiated thyroid cancer: can endoscopic thyroidectomy via a chest-breast approach achieve similar therapeutic effects as open surgery?

Authors:  Rui Qu; Jinyi Li; Jingge Yang; Peng Sun; Jian Gong; Cunchuan Wang
Journal:  Surg Endosc       Date:  2018-05-14       Impact factor: 4.584

9.  Evaluation of Acridine Orange Derivatives as DNA-Targeted Radiopharmaceuticals for Auger Therapy: Influence of the Radionuclide and Distance to DNA.

Authors:  Edgar Pereira; Letícia do Quental; Elisa Palma; Maria Cristina Oliveira; Filipa Mendes; Paula Raposinho; Isabel Correia; João Lavrado; Salvatore Di Maria; Ana Belchior; Pedro Vaz; Isabel Santos; António Paulo
Journal:  Sci Rep       Date:  2017-02-13       Impact factor: 4.379

Review 10.  Advances in Biomarker-Driven Targeted Therapies in Thyroid Cancer.

Authors:  Prachi Mishra; Dipranjan Laha; Robert Grant; Naris Nilubol
Journal:  Cancers (Basel)       Date:  2021-12-09       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.